Daito Pharmaceutical Co.,Ltd.
4577.T · JPX
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥50,643,000 | ¥46,895,000 | ¥45,101,000 | ¥43,464,000 |
| % Growth | 8% | 4% | 3.8% | – |
| Cost of Goods Sold | ¥42,005,000 | ¥37,056,000 | ¥34,770,000 | ¥32,005,000 |
| Gross Profit | ¥8,638,000 | ¥9,839,000 | ¥10,331,000 | ¥11,459,000 |
| % Margin | 17.1% | 21% | 22.9% | 26.4% |
| R&D Expenses | ¥0 | ¥2,349,000 | ¥1,865,000 | ¥1,749,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥6,017,000 | ¥3,431,000 | ¥3,078,000 | ¥2,990,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥165,000 | ¥180,000 | ¥166,000 |
| Operating Expenses | ¥6,017,000 | ¥5,945,000 | ¥5,123,000 | ¥4,905,000 |
| Operating Income | ¥2,621,000 | ¥3,894,000 | ¥5,207,000 | ¥6,553,000 |
| % Margin | 5.2% | 8.3% | 11.5% | 15.1% |
| Other Income/Exp. Net | ¥337,000 | ¥324,000 | -¥130,000 | ¥167,000 |
| Pre-Tax Income | ¥2,958,000 | ¥4,218,000 | ¥5,076,000 | ¥6,720,000 |
| Tax Expense | ¥1,192,000 | ¥1,040,000 | ¥1,549,000 | ¥2,092,000 |
| Net Income | ¥1,908,000 | ¥3,295,000 | ¥3,600,000 | ¥4,668,000 |
| % Margin | 3.8% | 7% | 8% | 10.7% |
| EPS | 62.72 | 105 | 113.82 | 152.45 |
| % Growth | -40.3% | -7.7% | -25.3% | – |
| EPS Diluted | 62.72 | 105 | 113.71 | 152.45 |
| Weighted Avg Shares Out | 30,422 | 15,691 | 15,815 | 15,310 |
| Weighted Avg Shares Out Dil | 30,422 | 15,691 | 15,828 | 15,310 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥1,000 | ¥0 | ¥0 | ¥0 |
| Interest Expense | ¥123,000 | ¥41,000 | ¥12,000 | ¥9,000 |
| Depreciation & Amortization | ¥4,332,000 | ¥3,659,000 | ¥3,870,000 | ¥3,313,000 |
| EBITDA | ¥7,413,000 | ¥7,920,000 | ¥8,958,000 | ¥9,881,000 |
| % Margin | 14.6% | 16.9% | 19.9% | 22.7% |